Decoy Therapeutics (NASDAQ:DCOY) Short Interest Down 84.7% in July

Decoy Therapeutics (NASDAQ:DCOY) was the recipient of a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 23,986 shares, a decline of 84.7% from the June 30th total of 156,313 shares. Currently, 4.6% of the company’s stock are short sold. Based on an average daily volume of 44,863 shares, the days-to-cover ratio is currently 0.5 days.

Decoy Therapeutics Price Performance

Shares of NASDAQ DCOY traded down $1.16 during mid-day trading on Monday, reaching $3.88. 1,024,010 shares of the company were exchanged, compared to its average volume of 194,118. The company has a market capitalization of $2.06 million, a PE ratio of -0.04 and a beta of 0.59. The firm’s 50-day moving average is $6.44. Decoy Therapeutics has a twelve month low of $3.72 and a twelve month high of $415.80.

Decoy Therapeutics (NASDAQ:DCOY) last announced its quarterly earnings results on Friday, May 8th. The company reported ($4.18) EPS for the quarter. As a group, analysts expect that Decoy Therapeutics will post -12.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings raised Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, June 12th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $30.00.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.